Cannabis Stocks Enter 420 Week Bruised: MSOS ETF Down, GTI Holds the Line

The cannabis equity story heading into 420 week 2026 is one of divergence. The broad AdvisorShares Pure US Cannabis ETF (MSOS) — the closest thing to a benchmark for the multi-state operator universe — is down roughly 3 percent year to date, trading near $4.58. Curaleaf has slipped 1.4 percent in 2026, Trulieve is off 5.6 percent, and Green Thumb Industries is one of the few names in the green, up about 2 percent. For an industry hoping rescheduling would ignite a re-rating, those numbers are sobering.

But the underlying operating picture is more nuanced than the stock tape suggests. Q4 2025 earnings — mostly reported in late February and March — showed that the best-run multi-state operators are generating meaningful cash flow, paying down debt, and positioning themselves for a post-280E world whenever it arrives.

The MSOS Tape vs. the Operating Reality

MSOS is a useful sentiment gauge for U.S. cannabis, but it's a blunt instrument. The ETF is heavily concentrated in a handful of large MSOs and uses swap-based exposure because many custodians won't touch plant-touching equities directly. That structure amplifies volatility and magnifies dollar-weighted moves from any single large holder. When one or two big names miss, the whole ETF can look like it's in freefall even if half the portfolio is performing.

The broader context: MSOS has been under pressure since the initial post-rescheduling euphoria in late 2024 faded. Multiple expansion — investors paying a higher multiple for the same cash flow — requires a policy catalyst that keeps getting delayed. Trump advisor Roger Stone said in early April 2026 that someone in the administration is "holding up" the final rescheduling rule. Every week that passes without a signed rule pushes the next leg of equity appreciation further out.

That explains why Q4 2025 numbers mattered so much. With policy frozen, the question for equity investors became: which operators can generate enough cash flow to thrive even under 280E?

Green Thumb Industries: The Cash Flow Leader

Green Thumb Industries (ticker: GTBIF) has quietly become the MSO that institutional investors point to when they want to argue the sector is investable. Through the first three quarters of 2025, GTI posted revenue between $280 million and $293 million per quarter and maintained GAAP net income in both Q1 and Q3 — a rarity in a sector where most operators lose money on a GAAP basis. Q3 2025 GAAP net income came in at $23.3 million; Q1 was $8.3 million.

The fundamentals behind those numbers are consistent: disciplined capital allocation, limited exposure to the most oversupplied wholesale markets, and a retail footprint concentrated in limited-license states where pricing is more stable. GTI has been buying back shares since 2023, an unusual move in an industry that has historically favored dilutive acquisitions. Those buybacks, combined with GAAP profitability, are why the stock is up in 2026 while peers are down.

Is GTI expensive? Depends on the lens. On a forward EV/EBITDA basis, GTI trades at a premium to peers like Cresco Labs and Verano — but the premium compresses quickly if 280E is repealed, since all that operating cash would stop flowing to federal taxes.

Trulieve and Curaleaf: The Scale Story

Trulieve reported $888 million in revenue through the first three quarters of 2025, $214 million in cash flow, and a 60 percent gross margin. Just as importantly, the company paid down $368 million in debt — a meaningful deleveraging in a sector where capital structure is often the binding constraint. Florida remains Trulieve's anchor market; Florida's 2026 medical cannabis sales surpassed 5.9 billion milligrams of THC earlier this month and topped 2 million ounces of smokable flower, both records.

Curaleaf, the largest MSO by revenue, has had a tougher narrative. The company's international expansion — particularly Germany after that country's adult-use legalization took effect in 2024 — continues to be a long-duration thesis rather than an immediate contributor. Investors have pushed back on execution risk, and the stock has barely moved in 2026.

The broader lesson across the top MSOs: operating results are improving, debt is being paid down, and gross margins are stabilizing after the 2023-2024 compression. But absent a rescheduling catalyst, revenue growth has become a grinding, market-by-market exercise rather than the explosive expansion story of earlier years.

What's at Stake Around 420

420 weekend is traditionally the busiest revenue period of the year for cannabis retail — the industry's equivalent of Black Friday. Dispensary chains typically pull 20 to 40 percent more traffic during the 4/18–4/20 window than a standard weekend, and many operators front-load promotions to convert occasional users into repeat buyers. With 4/20 landing on a Monday in 2026, the promotional window extends across most of the prior weekend.

Investors will be watching three things coming out of this year's 420:

Same-store sales commentary. Analysts typically get preliminary color on 420 sales during Q1 earnings calls in May. Any operator meaningfully exceeding same-store sales trends heading into the holiday will get credit for market-share gains.

Beverage and edibles mix. Cannabis beverages are eating into alcohol sales, according to multiple 2026 studies, and high-margin edibles and pre-rolls have become disproportionately profitable categories. Operators with strong beverage and edibles assortments — Trulieve and GTI both fit — stand to out-earn peers during a promotional weekend.

Tone on rescheduling. Management teams have been noticeably quieter about rescheduling in recent earnings calls, a shift that signals either lowered expectations or genuine uncertainty. Any change in tone during May earnings would move the entire sector.

The 2026 Investor Playbook

Most institutional cannabis analysts have shifted to a barbell positioning for 2026: own the cash-flow leaders (GTI, Trulieve) at reasonable multiples, avoid operators with stretched balance sheets or concentrated exposure to oversupplied wholesale markets, and size positions smaller than historical norms because of the persistent policy overhang.

The bull case is straightforward: if Schedule III rescheduling is finalized in 2026, 280E goes away and the sector's cash flow profile transforms overnight. GAAP earnings could roughly double for the most tax-exposed operators. The bear case is equally straightforward: rescheduling stalls indefinitely, state markets continue to mature at a grinding pace, and equity returns remain sub-market.

For 420 week specifically, the stock-specific catalysts are limited — this is a retail holiday, not an earnings event. But the operating data generated across April will set the tone for the May earnings cycle that will, in turn, set the 2026 cannabis investing narrative.

Key Takeaways

• The MSOS cannabis ETF is down about 3 percent year to date in 2026, reflecting faded post-rescheduling euphoria rather than deteriorating fundamentals.
• Green Thumb Industries is the cash flow leader among top MSOs, posting $23.3 million in Q3 2025 GAAP net income and trading up 2 percent in 2026 against a weak sector.
• Trulieve generated $888 million in revenue through the first three quarters of 2025, paid down $368 million in debt, and maintained a 60 percent gross margin.
• Federal rescheduling remains stalled as of mid-April 2026, removing the near-term catalyst that could justify multiple expansion across the sector.
• 420 weekend is the industry's biggest retail event; analysts will parse same-store sales commentary and product-mix trends during May earnings calls for directional signals on the rest of 2026.

Explore cannabis news, find dispensaries, and join the community at Budpedia.